F.H. van Bruggen

Faculteit Medische Wetenschappen/UMCG

Telefoon:

E-mail:

f.h.van.bruggen umcg.nl

ORCID Research Portal

Publicaties

Rethinking Cholesterol-lowering Medication: Exploring Disease Delay, Serious Adverse Events, and Room for Discontinuation

van Bruggen, F., 2025, [Groningen]: University of Groningen. 225 blz.

Onderzoeksoutput

Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study

van Bruggen, F. H., Zuidema, S. U. & Luijendijk, H. J., 22-jun.-2024, In: BMC Medical Research Methodology. 24, 13 blz., 137.

Onderzoeksoutput › › peer review

Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects

van Bruggen, F. H., de Haas, E. C., Zuidema, S. U. & Luijendijk, H. J., nov.-2024, In: American journal of cardiovascular drugs. 24, blz. 743-752 10 blz.

Onderzoeksoutput › peer review

Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER

van Bruggen, F. H. & Luijendijk, H. J., jan.-2022, In: American journal of cardiovascular drugs. 22, 1, blz. 5-8 4 blz.

Onderzoeksoutput › › peer review

Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U. & Luijendijk, H. J., 21-jan.-2021, In: Expert Review of Clinical Pharmacology. 14, 2, 2 blz.

Onderzoeksoutput › › peer review

Alle (8) publicaties

Bekijk volledig onderzoeksprofiel

F.H. van Bruggen

Publicaties

Rethinking Cholesterol-lowering Medication: Exploring Disease Delay, Serious Adverse Events, and Room for Discontinuation

Quantitative assessment of baseline imbalances in evolocumab and alirocumab trials: a meta-epidemiological study

Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects

Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER

Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review

LDL: hoe lager, hoe duurder

What the diabetes data in the FOURIER trial fail to show